Hyperthermic intraperitoneal chemotherapy (HIPEC) plus systemic chemotherapy versus systemic chemotherapy alone in locally advanced gastric cancer after D2 radical resection: a randomized-controlled study

[1]  Fangzhou Jia,et al.  Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer , 2022, Oncoimmunology.

[2]  Huachu Deng,et al.  The short- and long-term survival of hyperthermic intraperitoneal chemotherapy (HIPEC) in the advanced gastric cancer with/without peritoneal carcinomatosis: a systematic review and meta-analysis of randomized controlled trials , 2022, Updates in Surgery.

[3]  Y. Kodera,et al.  A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer , 2022, Gastric Cancer.

[4]  Cheng-gang Jiang,et al.  Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined with Surgery: A 12-Year Meta-Analysis of this Promising Treatment Strategy for Advanced Gastric Cancer at Different Stages , 2022, Annals of Surgical Oncology.

[5]  Yoon-Koo Kang,et al.  Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. , 2022, The Lancet. Oncology.

[6]  F. Lordick,et al.  Primary and metastatic peritoneal surface malignancies , 2021, Nature Reviews Disease Primers.

[7]  Jae Hyun Kim,et al.  PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Ajani,et al.  First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial , 2021, The Lancet.

[9]  B. Badgwell,et al.  Current treatment and recent progress in gastric cancer , 2021, CA: a cancer journal for clinicians.

[10]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[11]  Joon-Oh Park,et al.  A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  H. Grabsch,et al.  Gastric cancer , 2020, The Lancet.

[13]  Ling Huang,et al.  Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study , 2020, BMC Cancer.

[14]  T. Xie,et al.  Role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer , 2020, World journal of gastrointestinal oncology.

[15]  A. Diniz,et al.  Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensity‐score matched analysis , 2020, Journal of surgical oncology.

[16]  Zhen Wang,et al.  Issues on peritoneal metastasis of gastric cancer: an update , 2019, World Journal of Surgical Oncology.

[17]  R. van Hillegersberg,et al.  Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer—A Systematic Review , 2019, Journal of clinical medicine.

[18]  Wentao Liu,et al.  Prophylactic HIPEC with radical D2 gastrectomy improves survival and peritoneal recurrence rates for locally advanced gastric cancer: personal experience from a randomized case control study , 2019, BMC Cancer.

[19]  S. Msika,et al.  Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  W. Ceelen.  HIPEC with oxaliplatin for colorectal peritoneal metastasis: The end of the road? , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  Zhaohui J. Cai,et al.  Comparative effectiveness of hyperthermic intraperitoneal chemotherapy for gastric cancer , 2018, Medicine.

[22]  K. Turaga,et al.  Evolving Treatment Strategies and Outcomes in Advanced Gastric Cancer with Peritoneal Metastasis. , 2018, Surgical oncology clinics of North America.

[23]  Rebecca M. Dodson,et al.  Techniques for Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy , 2018, Annals of Surgical Oncology.

[24]  Y. Fong,et al.  The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. , 2017, European journal of cancer.

[25]  Yuanyu Wu,et al.  Progress in the treatment of advanced gastric cancer , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[26]  Japanese Gastric Cancer Association.  Japanese gastric cancer treatment guidelines 2014 (ver. 4) , 2016, Gastric Cancer.

[27]  Deepesh Agarwal,et al.  Complications of Cytoreductive Surgery and HIPEC in the Treatment of Peritoneal Metastases , 2016, Indian Journal of Surgical Oncology.

[28]  L. Ansaloni,et al.  Advanced gastric cancer: What we know and what we still have to learn. , 2016, World journal of gastroenterology.

[29]  Sabine Rohrmann,et al.  Changes in autopsy rates among cancer patients and their impact on cancer statistics from a public health point of view: a longitudinal study from 1980 to 2010 with data from Cancer Registry Zurich , 2015, Virchows Archiv.

[30]  L. Lorenzon,et al.  Lymph-Node Ratio Classification Strongly Correlates with Cancer Survivals of Patients Who Underwent R0 Resection for Gastric Cancer with More than 15 Nodes Harvested , 2014, European Surgical Research.

[31]  T. Fetsych,et al.  Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: Results of a single-centre retrospective study , 2014, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[32]  L. Ansaloni,et al.  The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art , 2014, International journal of surgical oncology.

[33]  V. Lemmens,et al.  Peritoneal carcinomatosis of gastric origin: A population‐based study on incidence, survival and risk factors , 2014, International journal of cancer.

[34]  C. Mello,et al.  Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients , 2012, World Journal of Surgical Oncology.

[35]  Y. Bang,et al.  Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial , 2012, The Lancet.

[36]  Joon-Oh Park,et al.  Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  S. Bruin,et al.  8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal Cancer , 2008, Annals of Surgical Oncology.

[38]  N. Demartines,et al.  Classification of Surgical Complications: A New Proposal With Evaluation in a Cohort of 6336 Patients and Results of a Survey , 2004, Annals of Surgery.

[39]  P. Sugarbaker,et al.  Gastrectomy, peritonectomy, and perioperative intraperitoneal chemotherapy: the evolution of treatment strategies for advanced gastric cancer. , 2003, Seminars in surgical oncology.

[40]  H. Shimada,et al.  Lack of efficacy of prophylactic continuous hyperthermic peritoneal perfusion on subsequent peritoneal recurrence and survival in patients with advanced gastric cancer. , 2002, Surgery.

[41]  K. Hirose,et al.  Efficacy of Continuous Hyperthermic Peritoneal Perfusion for the Prophylaxis and Treatment of Peritoneal Metastasis of Advanced Gastric Cancer: Evaluation by Multivariate Regression Analysis , 1999, Oncology.